TrialsgrambetaRCTs are beautiful

ASPEN

2025

Brensocatib in Non-Cystic-Fibrosis Bronchiectasis

In 1,721 patients with non-CF bronchiectasis and ≥2 exacerbations in the prior year, brensocatib 10 mg or 25 mg daily reduced annual exacerbation rate compared with placebo.

Result

Primary endpoint: Annualised exacerbation rate over 52 weeks

1.02 (10 mg) / 1.04 (25 mg) vs 1.29 (placebo); rate ratios 0.79 (p=0.004) and 0.81 (p=0.005). FEV1 decline reduced 38 mL/year (25 mg).

Original publication
Subtopic
DPP-1 inhibitor
Design
Multicentre phase-3 RCT
Relevance
Important: one of several pillars.
Source
Chalmers JD, et al. N Engl J Med. 2025;392(16):1569-1581.doi 10.1056/NEJMoa2411664

Discussion & critique

FDA approved August 2025 as Brinsupri, the first targeted therapy for non-CF bronchiectasis.